Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02234063 · ClinicalTrials.gov registry record · NA
Genetic Testing to Understand and Address Renal Disease Disparities
A NA study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- NA
- Development phase
- 2,052
- Enrollment target
NCT02234063 is a NA study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 2,052 participants.
The verdict
NCT02234063, a NA study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,052 participants
- Enrollment target
Study Summary
In this genomic medicine implementation pilot project, the investigators aim to conduct a randomized trial in a network of community health centers and primary care facilities to study processes, effects and challenges of incorporating information for apolipoprotein L1 (APOL1)-attributable genetic risk for end stage kidney disease in patients of African ancestry with hypertension .
Interventions
- OTHER Immediate Genetic Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,052 participants |
| Start Date | 2014-11 |
| Est. Completion | 2018-01-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02234063
The ClinicalTrials.gov registry entry for NCT02234063 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 2,052 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Immediate Genetic Testing is the first listed.
NCT02234063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02234063 about?
NCT02234063 is a clinical study titled "Genetic Testing to Understand and Address Renal Disease Disparities". In this genomic medicine implementation pilot project, the investigators aim to conduct a randomized trial in a network of community health centers and primary care facilities to study processes, effects and challenges of incorporating information for apolipoprotein L1 (APOL1)-attributable genetic r...
What is the current status of trial NCT02234063?
This trial is currently completed. It is a NA study. The enrollment target is 2,052 participants. The study started on 2014-11. Estimated completion is 2018-01-12.
What interventions are being tested in trial NCT02234063?
The interventions under investigation include: Immediate Genetic Testing (OTHER).
Who is sponsoring clinical trial NCT02234063?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.